A ferret model of COPD-related chronic bronchitis

JCI Insight

Volumn 1, Issue 15, 2016, Pages

  Raju, S Vamsee ^a   Kim, Hyunki ^b   Byzek, Stephen A ^a   Tang, Li Ping ^a   Trombley, John E ^a   Jackson, Patricia ^a,c   Rasmussen, Lawrence ^a   Wells, J Michael ^a,c,d   Libby, Emily Falk ^a,d   Dohm, Erik ^e   Winter, Lindy ^f   Samuel, Sharon L ^b   Zinn, Kurt R ^b   Blalock, J Edwin ^a,c,d   Schoeb, Trenton R ^d,g   Dransfield, Mark T ^a,c,d   Rowe, Steven M ^a,c,d,f,h  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Animal Resources Program   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85055597719     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.87536     Document Type: Article

References (53)

1. National Heart, Lung, and Blood Institute. Unpublished Tabulations of the National Health Interview Survey, 2010. http://www.cdc.gov/nchs/nhis/nhis_2010_data_release.htm. Updated December 14, 2012. Accessed September 21, 2016.
2. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45.
3. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364(9435):709–721.
4. Rabe KF, Beghe B, Luppi F, Fabbri LM. Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med. 2007;175(12):1222–1232.
5. Saetta M, et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med. 2000;161(3 Pt 1):1016–1021.
6. Morgan L, et al. Scintigraphic measurement of tracheal mucus velocity in vivo. Eur Respir J. 2004;23(4):518–522.
7. Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Respir Crit Care Med. 2002;166(9):1240–1247.
8. Moller W, et al. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am J Respir Crit Care Med. 2008;177(4):426–432.
9. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001.
10. Rab A, Rowe SM, Raju SV, Bebok Z, Matalon S, Collawn JF. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am J Physiol Lung Cell Mol Physiol. 2013;305(8):L530–L541.
11. Raju SV, Solomon GM, Dransfield MT, Rowe SM. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in chronic bronchitis and other diseases of mucus clearance. Clin Chest Med. 2016;37(1):147–158.
12. Hogg JC, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653.
13. Wells JM, et al. An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190(1):51–61.
14. Martinez-Garcia MA, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140(5):1130–1137.
15. Allinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JA. The presence of chronic mucus hypersecretion across adult life in relation to chronic obstructive pulmonary disease development. Am J Respir Crit Care Med. 2016;193(6):662–672.
16. Hogg JC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med. 2007;176(5):454–459.
17. Groneberg DA, Chung KF. Models of chronic obstructive pulmonary disease. Respir Res. 2004;5:18.
18. Sun X, et al. Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator-knockout ferrets. Am J Respir Cell Mol Biol. 2014;50(3):502–512.
19. Sun X, et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest. 2010;120(9):3149–3160.
20. Dransfield MT, et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest. 2013;144(2):498–506.
21. Raju SV, et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med. 2013;188(11):1321–1330.
22. Rasmussen RE, Mannix RC, Oldham MJ, Phalen RF. Effects of nitrogen dioxide on respiratory tract clearance in the ferret. J Toxicol Environ Health. 1994;41(1):109–120.
23. Vestbo J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365.
24. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science. 1997;277(5334):2002–2004.
25. Erb-Downward JR, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS One. 2011;6(2):e16384.
26. Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:229–238.
27. Vestbo J, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006;173(1):79–83.
28. Celli BR, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012.
29. Jean-Pierre H, Darbas H, Jean-Roussenq A, Boyer G. Pathogenicity in two cases of Staphylococcus schleiferi, a recently described species. J Clin Microbiol. 1989;27(9):2110–2111.
30. Latorre M, Rojo PM, Unzaga MJ, Cisterna R. Staphylococcus schleiferi: a new opportunistic pathogen. Clin Infect Dis. 1993;16(4):589–590.
31. Bingel SA. Pathology of a mouse model of x-linked chronic granulomatous disease. Contemp Top Lab Anim Sci. 2002;41(5):33–38.
32. Tantucci C, et al. Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease. Respir Med. 2008;102(4):613–619.
33. Thurlbeck WM. Overview of the pathology of pulmonary emphysema in the human. Clin Lab Med. 1984;4(3):539–559.
34. Robbesom AA, et al. Aberrant fibrillin-1 expression in early emphysematous human lung: a proposed predisposition for emphysema. Mod Pathol. 2008;21(3):297–307.
35. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153(5):1530–1535.
36. Vestbo J. Epidemiological studies in mucus hypersecretion. Novartis Found Symp. 2002;248:3–12; discussion 12.
37. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25(8):2043–2048.
38. Kim YJ, et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study. Korean J Intern Med. 2012;27(4):426–435.
39. Partridge MR, Miravitlles M, Ståhl E, Karlsson N, Svensson K, Welte T. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J. 2010;36(1):96–104.
40. Small M, Broomfield S, Pollard R, Fermer S. Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities. Eur Respir J. 2012;40(56): P3476.
41. Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:112.
42. Martinez CH, et al. The clinical impact of non-obstructive chronic bronchitis in current and former smokers. Respir Med. 2014;108(3):491–499.
43. Hogg JC. State of the art. Bronchiolitis in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(6):489–493.
44. Friedlander AL, Lynch D, Dyar LA, Bowler RP. Phenotypes of chronic obstructive pulmonary disease. COPD. 2007;4(4):355–384.
45. Kim V, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626–633.
46. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–2365.
47. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465–471.
48. Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52(8):2813–2823.
49. Larsen JM, et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS ONE. 2012;7(2):e31976.
50. Donaldson GC, et al. Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192(8):943–950.
51. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852.
52. Regan EA, et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA Intern Med. 2015;175(9):1539–1549.
53. Bowler RP, et al. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest. 2014;146(4):941–950.